ScholarIQanswers from OpenAlex

Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence

PaperCitations, authors & open-access status

Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence have?

ScholarIQcitation count

Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence has 63 citations in the OpenAlex counts ScholarIQ stores.

When was Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence published?

ScholarIQyear

Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence has 2020 year in the ScholarIQ index.

What is the open-access status of Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence?

ScholarIQoa status

Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence has gold oa status in the ScholarIQ index.

What is the DOI of Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence?

ScholarIQdoi

The DOI for Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence is on the source record.

What is the PMID of Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence?

ScholarIQpmid

The PMID for Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence is on the source record.

What is the OpenAlex record for Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence?

ScholarIQopenalex

The OpenAlex for Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial